/

STTK

Shattuck Labs, Inc.Open

5.56−0.53 −8.70%USD

NasdaqGS · as of Oct 13, 15:49 ET · 15m delay

Open

6.06

Prev close

6.09

Day range

5.556.09

52-week range

1.708.33

Volume

1.30M1.06×

Mkt cap

558.02M

P/E ttm

—

Fwd P/E

-10.76

EPS ttm

-0.4700

Div yield

0.00%

Earnings

Aug 11, 2026

From 52w high

−33.25%

Price Chart

Yahoo Finance · delayed

STTKOct 13, 2026O 6.06H 6.09L 5.55C 5.56−0.53 (−8.70%)Vol 1.30M

SMA 506.75
SMA 2005.94

1Y change +202.17% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

STTK Shattuck Labs, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.12%
1 month: −10.32%
3 months: −11.61%
6 months: −17.99%
Year to date: +52.33%
1 year: +202.17%

Valuation & ownership

Market cap: 558.02M
Enterprise value: 405.58M
P/E (ttm): —
Forward P/E: -10.76
PEG ratio: —
Price / book: 2.65
Price / sales (ttm): 558.02
EV / EBITDA: -7.78
EPS (ttm): -0.4700
EPS (forward): -0.5170
Beta (5y monthly): 1.10
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 100.36M
Float: 67.76M
Short % of float: 11.30%
Short ratio (days): 8.22
Held by insiders: 4.08%
Held by institutions: 80.16%
Avg volume (3m): 1.22M
50-day average: 6.79
200-day average: 5.93
52-week change: +202.17%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 37.1
vs 50-day SMA: −17.69%
vs 200-day SMA: −6.42%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.32%
Realised vol (20d, ann.): 70.3%
From 52-week high: −33.25%
From 52-week low: +227.06%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

15.40

+176.98% implied

Low 10.00Median 15.50High 19.00

Recommendation trend

Now12 / 0 / 0
1m ago11 / 0 / 0

DES

About Shattuck Labs, Inc.

Yahoo Finance profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Sector: Healthcare
Industry: Biotechnology
Employees: 40
Headquarters: Austin, TX, United States
Website: shattucklabs.com
Officers: Dr. Taylor H. Schreiber M.D., Ph.D. Co-Founder, CEO & Director
Mr. Andrew R. Neill M.B.A. Chief Financial Officer
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D. Chief Medical Officer
Mr. Brad Huckabee Vice President of Accounting & SEC reporting

SEAS

Seasonality · STTK

2020–2026 · monthly returns

Strongest month Dec +65.70%Weakest month Mar −21.47%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	6.0	1.3	64.0	11.2	-16.8	16.6	1.9	-0.8	-2.7	-18.5			+52.3%
2025	-4.1	13.8	-28.0	4.1	2.1	-21.6	-3.8	28.7	143.6	-19.7	9.4	73.8	+201.7%
2024	32.4	-7.5	2.4	17.2	-29.6	-47.7	3.1	-9.8	-2.8	-63.9	-12.7	10.0	−83.0%
2023	81.3	13.2	-37.7	2.0	-7.7	12.6	-18.3	-15.3	-29.6	6.6	21.0	263.8	+210.0%
2022	-18.8	-27.6	-14.8	-9.9	-25.5	42.0	-6.2	-14.7	-16.9	-1.9	-14.3	1.3	−73.0%
2021	-5.3	-16.8	-29.2	28.9	-28.0	6.8	-24.0	-4.1	-3.5	-5.3	-56.1	0.4	−83.8%
2020											39.9	44.9	+102.7%

INSD

Insider Activity · STTK

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

15.94M shares

Sells, 6 months

85.9K shares

Net shares

+15.85M

Net change in insider shares

−134.80%

Date	Insider	Transaction	Shares	Value
Jul 5, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Conversion of Exercise of derivative security at price 3.57 per share.	12.6K	$44.85K
Jul 1, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Sale at price 7.01 per share.	410	$2.87K
Jun 30, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Sale at price 7.07 - 7.08 per share.	23.5K	$166.13K
Jun 30, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Conversion of Exercise of derivative security at price 3.57 per share.	23.5K	$83.77K
Jun 29, 2026	Pandite Arundathy N.Officer	Sale at price 7.01 per share.	30K	$210.30K
Jun 8, 2026	Siegall Clay BDirector	Purchase at price 4.00 per share.	62.5K	$250.00K
Jun 7, 2026	Ashiya MonaDirector	Conversion of Exercise of derivative security at price 3.90 per share.	15.37M	$59.93M
May 21, 2026	Siegall Clay BDirector	Stock Award(Grant) at price 6.10 per share.	128.1K	$781.13K
May 21, 2026	Siegall Clay BDirector	Conversion of Exercise of derivative security at price 6.10 per share.	128.1K	$781.13K
May 20, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Stock Award(Grant) at price 6.09 per share.	5.1K	$31.19K
May 20, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Conversion of Exercise of derivative security at price 6.09 per share.	5.1K	$31.19K
May 14, 2026	Stout StephenGeneral Counsel	Stock Award(Grant) at price 6.26 per share.	12.8K	$80.16K
May 14, 2026	Stout StephenGeneral Counsel	Conversion of Exercise of derivative security at price 6.26 per share.	12.8K	$80.16K
May 11, 2026	Pandite Arundathy N.Officer	Sale at price 6.61 per share.	30K	$198.30K
May 11, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Sale at price 7.01 per share.	2K	$14.24K
May 11, 2026	Schreiber Taylor M.D., Ph.D.Chief Executive Officer	Stock Award(Grant) at price 6.62 per share.	25.6K	$169.54K
May 11, 2026	Neill Andrew R.Chief Financial Officer	Stock Award(Grant) at price 6.62 per share.	64K	$423.86K
May 11, 2026	Schreiber Taylor M.D., Ph.D.Chief Executive Officer	Conversion of Exercise of derivative security at price 6.62 per share.	25.6K	$169.54K
May 11, 2026	Neill Andrew R.Chief Financial Officer	Conversion of Exercise of derivative security at price 6.62 per share.	64K	$423.86K
May 11, 2026	Shukla Abhinav A. Ph.D.Chief Technology Officer	Conversion of Exercise of derivative security at price 3.57 per share.	2K	$7.25K

13F

Investors Holding STTK

latest 13F filings of 29 followed managers

Investors holding STTK
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$5.2M	0.01%	743.76K	+23%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

STTK

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

STTK

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Shattuck Labs, Inc.

Seasonality · STTK

Insider Activity · STTK

Congress Trades · STTK

Investors Holding STTK

Investors Holding STTK

Congress Trades · STTK

Insider Activity · STTK

Seasonality · STTK

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Shattuck Labs, Inc.

Financial Snapshot

Earnings & Dividends

News